Last reviewed · How we verify
Ilumya Injectable Product
Ilumya (tildrakizumab) is a monoclonal antibody that selectively blocks the IL-23 pathway by binding to the p19 subunit of interleukin-23, reducing inflammatory signaling in psoriasis.
Ilumya (tildrakizumab) is a monoclonal antibody that selectively blocks the IL-23 pathway by binding to the p19 subunit of interleukin-23, reducing inflammatory signaling in psoriasis. Used for Moderate to severe plaque psoriasis.
At a glance
| Generic name | Ilumya Injectable Product |
|---|---|
| Sponsor | Psoriasis Treatment Center of Central New Jersey |
| Drug class | IL-23 inhibitor (monoclonal antibody) |
| Target | IL-23 p19 subunit |
| Modality | Small molecule |
| Therapeutic area | Immunology/Dermatology |
| Phase | FDA-approved |
Mechanism of action
IL-23 is a key cytokine involved in the pathogenesis of psoriasis, particularly in driving Th17 cell differentiation and skin inflammation. By selectively targeting the p19 subunit of IL-23, tildrakizumab prevents IL-23 signaling while sparing IL-12, which may reduce the risk of certain immune-related adverse events. This mechanism leads to suppression of psoriatic inflammation and improvement in skin lesions.
Approved indications
- Moderate to severe plaque psoriasis
Common side effects
- Upper respiratory tract infection
- Injection site reactions
- Headache
Key clinical trials
- Long Term Evaluation of Safety and Efficacy of Tildrakizumab in Patients With Psoriatic Arthritis (PHASE3)
- SKIN Disease Profiling by an Exploratory, pRospective, Biomarker Study in dermatoloGY Practice (SKINERGY)
- Therapeutic Drug Monitoring of Tildrakizumab in Psoriasis Patients (PHASE4)
- Efficacy and Safety of Tildrakizumab 100 Milligrams (mg) in Participants With Moderate-Severe Chronic Plaque Psoriasis and Its Impact on Their Quality of Life (TRIBUTE) (PHASE4)
- Efficacy and Safety of Tildrakizumab in Participants With Moderate-to-Severe Chronic Plaque Psoriasis Who Are Non-Responders to Dimethyl Fumarate Therapy (PHASE4)
- ILUMYA in Combination With HALOG Ointment 0.1% for Plaque Psoriasis. (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ilumya Injectable Product CI brief — competitive landscape report
- Ilumya Injectable Product updates RSS · CI watch RSS
- Psoriasis Treatment Center of Central New Jersey portfolio CI